10 Result(s)
within
Medicine & Public Health
Pharmacology/Toxicology
Jorge Cortes
Article
-
Article
Open AccessConcentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory a...
-
Article
Open AccessAnalysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
Cardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of ponatinib on cardiac...
-
Article
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
A phase I study was performed to determine the safety and pharmacokinetics of XK469R in patients with refractory acute leukemia. The study aimed to determine the maximum tolerated dose (MTD) and dose limiting ...
-
Article
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
Abstract
-
Article
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Abstract
-
Article
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
Abstract
-
Article
Phase I Study of Irofulven (MGI 114), an Acylfulvene Illudin Analog, in Patients with Acute Leukemia
Irofulven (MGI 114, 6-hydroxymethylacylfulvene, HMAF)is a semisynthetic illudin analog with broad in vitroanti-neoplastic activity. In this leukemia phase I study, weinvestigated the toxicity profile and activity...
-
Article
Promising Approaches in Acute Leukemia
In the last few decades, there has been a significant improvement in theprognosis of patients with acute leukemias. Still, the majority ofpatients succumb to these diseases. In recent years there has been a gr...
-
Article
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
The topoisomerase I inhibitor topotecan has shown activity in acute myeloid leukemia (AML) and myelodysplastic syndromes. The present study was designed to assess whether topotecan with cytosine arabinoside (a...
-
Article
Phase I study of liposomal daunorubicin in patients with acute leukemia
The dose of anthracyclines used during induction has been identified as a significant prognostic factor in acute leukemias. Liposomal encapsulation of anthracyclines has been proposed as a way of decreasing to...
